3 Million Canadians Use GLP-1 Drugs, Survey Reveals High Demand

Current Usage Numbers

The survey data indicates that millions of Canadians have already gained access to GLP-1 receptor agonist medications, representing a significant portion of the adult population. This includes patients using various formulations of semaglutide and tirzepatide products available through Canadian pharmacies.

The medications tracked in the survey include Wegovy, Ozempic, Mounjaro, and other Health Canada-approved GLP-1 formulations currently available at major pharmacy chains including Shoppers Drug Mart, Costco, and Walmart locations nationwide.

Access and Demand Patterns

Beyond current users, the survey suggests substantial unmet demand exists among Canadian adults seeking access to these medications. This demand spans multiple provinces including Ontario, British Columbia, Alberta, and Quebec, where patients continue seeking coverage through various channels.

• Current users: Approximately 3 million Canadian adults
• Additional demand: Survey indicates many more Canadians seeking access
• Geographic distribution: Usage reported across all major provinces
• Access methods: Combination of private insurance, cash payment, and public coverage where available

Market Impact

The 3 million user figure represents a substantial market for GLP-1 medications in Canada, with implications for both brand-name manufacturers and upcoming generic competitors. Health Canada currently reviews nine generic semaglutide applications, which could affect pricing and access for this large patient population.

Current cash prices for these medications range from $300-400 CAD monthly at Canadian pharmacies, though costs vary by specific product strength and quantity dispensed.

Regulatory Context

Health Canada continues its review process for generic alternatives, with semaglutide patents having expired January 4, 2026. The regulatory agency maintains its standard 180-day review timeline for generic drug applications, which could affect future access for the millions of current and prospective users.

Patients currently using these medications can track regulatory updates and pricing changes through our generic semaglutide tracker and check coverage options via our insurance coverage checker.

Looking Forward

The survey data provides Health Canada and provincial health authorities with concrete usage figures as they evaluate coverage decisions and regulatory approvals. For patients with questions about access options and current pricing, our FAQ section addresses common concerns about GLP-1 medications in Canada.

As generic competition potentially emerges later this year, the 3 million current users represent a significant patient population that could benefit from increased competition and potentially lower prices.